You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD34 Cells

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Sickle Cell Disease Trial in Paris (DREPAGLOBE drug product)

Active, not recruiting
  • Sickle Cell Disease
  • DREPAGLOBE drug product
  • Paris, France
    Department of Biotherapy, Necker-Enfants Malades Hospital
Sep 26, 2022

Mitochondrial Diseases, Pearson Syndrome Trial in Ramat Gan (MNV-201)

Recruiting
  • Mitochondrial Diseases
  • Pearson Syndrome
  • MNV-201
  • Ramat Gan, Israel
    Sheba Medical Center
Aug 24, 2023

P47-Phox, Deficiency of Trial in London (Lentiviral vector transduced CD34+ cells)

Not yet recruiting
  • P47-Phox, Deficiency of
  • Lentiviral vector transduced CD34+ cells
  • London, United Kingdom
    Great Ormond Street Hospital
Aug 2, 2022

Retinitis Pigmentosa Trial in Sacramento (Intravitreal autologous CD34+ cells)

Recruiting
  • Retinitis Pigmentosa
  • Intravitreal autologous CD34+ cells
  • Sacramento, California
    University of California Davis
Sep 1, 2022

Apheresis of Patients With Immunodeficiency

Recruiting
  • LAD-1
  • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Aug 24, 2022

    Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency Trial in Paris (ARTEGENE drug product)

    Not yet recruiting
    • Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency
    • ARTEGENE drug product
    • Paris, France
      Department of Pediatric Immunology, Hematology and Rheumatology
    Sep 26, 2022

    Transfusion-dependent a-Thalassemia Trial (GMCN-508A Drug Product)

    Not yet recruiting
    • Transfusion-dependent α-Thalassemia
    • GMCN-508A Drug Product
    • (no location specified)
    Feb 24, 2023

    Sickle Cell Disease Trial in Los Angeles (ßAS3-FB vector transduced peripheral blood CD34+ cells)

    Recruiting
    • Sickle Cell Disease
    • βAS3-FB vector transduced peripheral blood CD34+ cells
    • Los Angeles, California
      University of California, Los Angeles (UCLA)
    Apr 9, 2022

    AML, ALL, Lymphoid Malignancies Trial in Birmingham (Infusion of CD34 selected hematopoietic stem cells)

    Not yet recruiting
    • AML
    • +5 more
    • Infusion of CD34 selected hematopoietic stem cells
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Sep 14, 2023

    Severe Combined Immunodeficiency, X-Linked Trial in London (Lentiviral vector transduced CD34+ cells)

    Recruiting
    • Severe Combined Immunodeficiency, X-Linked
    • Lentiviral vector transduced CD34+ cells
    • London, Greater London, United Kingdom
      Great Ormond Street Hospital for Children NHS Foundation Trust
    Mar 15, 2022

    Severe Aplastic Anemia, MDS (Myelodysplastic Syndrome) Trial in Baltimore, Bethesda, Minneapolis (Miltenyi CD34 Reagent System,

    Recruiting
    • Severe Aplastic Anemia
    • MDS (Myelodysplastic Syndrome)
    • Miltenyi CD34 Reagent System
    • Donor derived G-CSF mobilized PBC
    • Baltimore, Maryland
    • +2 more
    Jan 25, 2023

    B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine

    Not yet recruiting
    • B-cell Non Hodgkin Lymphoma
    • Chronic Lymphocytic Leukemia
    • Cyclophosphamide injection
    • +2 more
    • Charleston, South Carolina
      Hollings Cancer Center at Medical University of South Carolina
    Jan 18, 2023

    Wiskott-Aldrich Syndrome Trial in Atlanta, Milan (OTL-103)

    Active, not recruiting
    • Wiskott-Aldrich Syndrome
    • OTL-103
    • Atlanta, Georgia
    • +1 more
    Sep 27, 2022

    Leukemia, Myelodysplastic Syndrome, Lymphoma Trial in New York (CliniMACS Fractionation system (Arm A), CliniMACS Fractionation

    Completed
    Has Results
    • Leukemia
    • +2 more
    • CliniMACS Fractionation system (Arm A)
    • +2 more
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Jul 12, 2022

    Hiv Trial in Philadelphia (Autologous CD4 T-Cells)

    Completed
    Has Results
    • Hiv
    • Autologous CD4 T-Cells
    • Philadelphia, Pennsylvania
      University of Pennsylvania
    Nov 13, 2022

    Non-exudative Age-related Macular Degeneration, Diabetic Retinopathy, Retina Vein Occlusion Trial in Sacramento (CD34+ bone

    Enrolling by invitation
    • Non-exudative Age-related Macular Degeneration
    • +4 more
    • CD34+ bone marrow stem cells intravitreal
    • Sacramento, California
      University of California Davis
    Aug 8, 2022

    Hematologic Disorders Trial in Aurora (Miltenyi CliniMACS® CD34 Reagent System)

    Recruiting
    • Hematologic Disorders
    • Miltenyi CliniMACS® CD34 Reagent System
    • Aurora, Colorado
      University of Colorado
    Feb 22, 2022

    Sickle Cell Disease Trial in Saint Louis (Motixafortide, Natalizumab, Leukapheresis)

    Not yet recruiting
    • Sickle Cell Disease
    • Saint Louis, Missouri
      Washington University School of Medicine
    Nov 8, 2022

    ß-thalassemia Trial (BD211)

    Not yet recruiting
    • β-thalassemia
    • BD211
    • (no location specified)
    Mar 15, 2023

    Adenosine Deaminase Severe Combined Immune Deficiency Trial (A cryopreserved formulation of autologous mPB CD34+ hematopoietic

    Not yet recruiting
    • Adenosine Deaminase Severe Combined Immune Deficiency
    • A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme
    • (no location specified)
    Jun 20, 2022

    Mucopolysaccharidosis II Trial (Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII)

    Not yet recruiting
    • Mucopolysaccharidosis II
    • Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII
    • (no location specified)
    Dec 16, 2022

    Sickle Cell Disease Trial in Birmingham, Palo Alto, Saint Louis (GPH101 Drug Product)

    Active, not recruiting
    • Sickle Cell Disease
    • GPH101 Drug Product
    • Birmingham, Alabama
    • +2 more
    Jan 5, 2023

    ß-thalassemia Trial in Shanghai (BD211)

    Not yet recruiting
    • β-thalassemia
    • BD211
    • Shanghai, China
      Shanghai Ruijin Hospital
    Mar 16, 2023

    CD34 + Stem Cells and Biological Markers of Angiogenesis in

    Recruiting
    • Vasculopathy
    • Heart Transplant Failure
    • coronary CT angiography
    • Ljubljana, Slovenia
      Advanced Heart Failure and Transplantation Center, University Me
    Aug 2, 2022

    B-Cell Acute Lymphoblastic Leukemia, Adult, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent Trial in Maywood (Fludarabine,

    Active, not recruiting
    • B-Cell Acute Lymphoblastic Leukemia, Adult
    • +2 more
    • Maywood, Illinois
      Loyola University
    Aug 11, 2022